The Influence of Excipients on the Physicochemical and Biological Properties of a Bactericidal, Labile Ester Prodrug in a Salt Form – A Case Study of Cefetamet Pivoxil Hydrochloride
DOI:
https://doi.org/10.24297/jac.v15i2.7560Keywords:
Cefetamet Pivoxyl, pharmaceutical formulations, bactericidal activity, drug carriersAbstract
The article presents an innovative approach to a bactericidal drug design based on a cephem prodrug analogue – cefetamet pivoxil hydrochloride. The emergence of cefetamet pivoxil hydrochloride excipient systems (mannitol, hydroxypropyl methyl cellulose, pregelatinised starch, lactose monohydrate, magnesium stearate, polyvinylpyrrolidone) caused changes in the physicochemical properties of cefetamet pivoxil hydrochloride. They are significant for planning the development of an innovative pharmaceutical formulation. The biological activity profile of the prodrug was also modified. FTIR spectra were used to study interactions between cefetamet pivoxil hydrochloride and the excipients. The theoretical approach to the analysis of experimental spectra enabled precise indication of cefetamet pivoxil hydrochloride domains responsible for interaction with the excipients. The interactions between cefetamet pivoxil hydrochloride and the excipients resulted in some important physicochemical modifications: acceptor fluid-dependent changes in solubility and the dissolving rate as well as a decrease in the chemical stability of cefetamet pivoxil hydrochloride in the solid state, especially during thermolysis. The interactions between cefetamet pivoxil hydrochloride and the excipients also had biologically essential effects. There were changes in its permeability through artificial biological membranes simulating the gastrointestinal tract, which depended on the pH value of the acceptor solution. Cefetamet pivoxil hydrochloride combined with the excipient systems exhibited greater bactericidal potential against Staphylococcus aureus. Its bactericidal potential against Enterococcus faecalis, Pseudomonas aeruginosa and Proteus mirabilis doubled. The new approach provides an opportunity to develop treatment of resistant bacterial infections. It will enable synergy between the excipient and the pharmacological potential of an active pharmaceutical substance with modified physicochemical properties induced by the drug carrier.
Downloads
References
English B. K. Limitations of beta-lactam therapy for infections caused by susceptible Gram-positive bacteria. J. Infect. 2014, 69, 5-9.
Cielecka-Piontek J.; Michalska K.; Zalewski P.; Jeli?ska A. Recent advances in stability studies of carbapenems. Curr. Pharm. Anal. 2011, 7, 213–227.
Alanis A. J. Resistance to Antibiotics: Are We in the Post-Antibiotic Era? Arch. Med. Res. 2005, 36, 697–705.
Ishikawa T.; Matsunaga N.; Tawada H.; Kuroda N.; Nakayama Y.; Ishibashi Y.; Tomimoto M.; Ikeda Y.; Tagawa Y.; Iizawa Y. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties, Bioorg. Med. Chem. 2003, 11, 2427–2437.
Flanagan S.; Bartizal K.; Minassian S.; Fang E.; Prokocimer P. In vitro, in Vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother. 2013, 57, 3060–3066.
Sohi H.; Sultana Y.; Khar R.K. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev. Ind. Pharm. 2004, 30, 429-448.
Zawilska J. B.; Wojcieszak J.; Olejniczak A. B. Prodrugs: A challenge for the drug development. Pharmacol. Rep. 2013, 65, 1–14.
Pinder N.; Brenner T.; Swoboda S.; Weigand M. A.; Hoppe-Tichy T. Therapeutic drug monitoring of beta-lactam antibiotics – Influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV. J. Pharm. Biomed. Anal. 2017, 143, 86–93.
Karimi K.; Katona G.; Csóka I.; Ambrus R. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride. J. Pharm. Biomed. Anal. 2018, 148, 73–79.
Zalewski P.; Skibi?ski R.; Talaczy?ska A.; Paczkowska M.; Garbacki P. Cielecka-Piontek J. Stability studies of cefoselis sulfate in the solid state. J. Pharm. Biomed. Anal. 2015, 114, 222–226.
Rodrigeuz-Pena R.; Antunez C.; Martin E.; Blanca-Lopez N.; Mayorga C.; Torres M. Allergic reactions to beta-lactams. Expert Opin. Drug Saf. 2013, 5, 31–48.
Kim J.Y.; Ha J.M.; Rhee Y.S.; Park C.W.; Chi S.C.; Park E.S. Influence of pharmaceutical excipients on stability of pramipexole dihydrochloride monohydrate in tablets. J. Pharm. Inv. 2014, 44, 177–185.
Paus R.; Prudic A.; Ji Y. Influence of excipients on solubility and dissolution of pharmaceuticals. Int. J. Pharm. 2015, 15, 277-287.
Parr A.; Hidalgo I. J.; Bode Ch.; Brown W.; Yazdanian M.; Gonzalez M. A.; Sagawa K.; Miller K.; Jiang W.; Stippler E. S. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers. Pharm, Res. 2016, 33, 167–176.
Panakanti R.; Narang A. S. Impact of Excipient Interactions on Drug Bioavailability from Solid Dosage Forms. Pharm. Res. 2012, 29, 2639-2659.
Cullman W.; Edwards D. J.; Kissling M.; Kneer J.; Stoeckel K.; Urwyler H. Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. Int. J. Antimicrob. Agents. 1992, 1, 175-91.
Frisch M. J.; Trucks G. W.; Schlegel H. B.; Scuseria G. E.; Robb M. A.; Cheeseman J. R.; Scalmani G.; Barone V.; Petersson G. A.; Nakatsuji H.; Li X.; Caricato M.; Marenich A. V.; Bloino J.; Janesko B. G.; Gomperts R.; Mennucci B.; Hratchian H. P.; Ortiz J. V.; Izmaylov A. F.; Sonnenberg J. L.; Williams-Young D.; Ding F.; Lipparini F.; Egidi F.; Goings J.; Peng B.; Petrone A.; Henderson T.; Ranasinghe D.; Zakrzewski V. G.; Gao J.; Rega N.; Zheng G.; Liang W.; Hada M.; Ehara M.; Toyota K.; Fukuda R.; Hasegawa J.; Ishida M.; Nakajima T.; Honda Y.; Kitao O.; Nakai H.; Vreven T.; Throssell K.; Montgomery J. A., Jr.; Peralta J. E.; Ogliaro F.; Bearpark M. J.; Heyd J. J.; Brothers E. N.; Kudin K. N.; Staroverov V. N.; Keith T. A.; Kobayashi R.; Normand J.; Raghavachari K.; Rendell A. P.; Burant J. C.; Iyengar S. S.; Tomasi J.; Cossi M.; Millam J. M.; Klene M.; Adamo C.; Cammi R.; Ochterski J. W.; Martin R. L.; Morokuma K.; Farkas O.; Foresman J. B.; Fox D. J. Gaussian 09, Revision D.01, Gaussian, Inc., Wallingford CT, 2009
Garbacki P.; Cielecka-Piontek J.; Zalewski P.; Oszczapowicz I.; Jeli?ska A. A simple and sensitive stability-indicating UHPLC-DAD method for the determination of cefetamet pivoxil hydrochloride. Acta Pol. Pharm. 2016, 73, 621-626.
Moore J.; Flanner H. Mathematical Comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Technol. 1996, 20, 64–74.
Shah V.; Tsong Y.; Sathe P.; Liu P. J. In vitro dissolution profile comparison - statistics and analysis of the similarity factor, f(2). Pharm. Res. 1998, 15, 889–896.
Validation of analytical procedures, Proceeding of the International Conference of Harmonisation (ICH). Commission of the European Comminities. 1996.
Yee S.In vitro permeability across Caco3 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 1997, 14, 763–766.
Microbial strains National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. Wayne Pa: National Committee for Clinical Laboratory Standards; 1997.
Del Franco M.; Paone L.; Novati R.; Giacomazzi C. G.; Bagattini M.; Galotto C.; Montanera P. G.; Triassi M.; Zarrilli R. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d'Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789), BMC Microbiol. 2015, 9;15(1): 260. doi: 10.1186/s12866-015-0597-z.
Papp-Wallace K. M.; Endimiani A.; Taracila M. A.; Bonomo R. A. Carbapenems: past, present and future, Antimicrob. Agents Chemother. 2011, 55, 4943–4960.
El-gamal M.; Brahim I.; Hisham N.; Aladdin R.; Mohammed H.; Bahaaelidn A. Recent updates of carbapenem antibiotics. Eur. J. Med. Chem. 2017, 5, 185-195.
Cielecka-Piontek J.; Szymanowska-Powa?owska D.; Paczkowska M.; ?ysakowski P.; Zalewski P.; Garbacki P. Stability, compatibility and microbiological activity studies of meropenem-clavulanate potassium. J. Antibiot. 2015, 68, 35–39.
Paczkowska M.; Mizera M.; Szymanowska-Powa?owska D.; Lewandowska K.; Go?cia?ska W. J. Pietrzak R. Cielecka-Piontek J. ?-Cyclodextrin complexation as an effective drug delivery system for meropenem. Eur. J. Pharm. Biopharm. 2016, 99, 24-34.
Lallemnad E.; Lacroix M. Z.; Toutain P. L.; Boullier S.; Ferran A. A.; Bousquet-Melou A. In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations. Front. Microbiol. 2016, 7, 2051.
Gavhane Y. N.; Yadav A. V. Loss of orally administered drugs in GI tract. Saudi Pharma. J. 2012, 20, 331–344.
Jeli?ska A.; Zaj?c M.; Dobrowolski L.; Medenecka B.; Ruci?ski P.; Oszczapowicz I. Kinetics of degradation of cefetamet pivaloyloxymethyl ester and its hydrochloride in solid phase. Acta Pol. Pharm. 2003, 60, 435-41.
Zalewski P.; Skibi?ski R.; Cielecka-Piontek J. Stability studies of cefpirome sulfate in the solid state: Identification of degradation products. J. Pharm. Biomed. Anal. 2014, 92, 22–25.
Cielecka-Piontek J.; Lewandowska K.; Barszcz B.; Czartek A. Solid-state stability studies of faropenem based on chromatography, spectroscopy and theoretical analysis. Drug Dev. Ind. Pharm. 2014, 40, 136-143.
Pinder N.; Brenner T.; Swoboda S.; Weigand M. A.; Hoppe-Tichy T. Therapeutic drug monitoring of beta-lactam antibiotics – Influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV. J. Pharm. Biomed. Anal. 2017, 143, 86–93.
Dong Z.; Choi D. S. Hydroxypropyl Methylcellulose Acetate Succinate: Potential Drug–Excipient Incompatibility. AAPS PharmSciTech. 2008, 9, 991–997.
Tamiris J.; Zamara I. F.; Garcia J. S.; Trevjsan M. G. Compatibility of sildenafil citrate and pharmaceutical excipients by thermal analysis and LC-UV, Pre-formulation and stability studies in sildenafila citrate in solid formulation. J. Therm. Anal. Cal. 2013, 111, 2037–2044.
Wu Y. M.; Levons J.; Narang A. S ; Raghavan K.; Rao V. M. Reactive Impurities in Excipients: Profiling, Identification and Mitigation of Drug–Excipient Incompatibility, AAPS PharmSciTech 2011, 12, 1248–1263.
Dail M. K.; Me?yk S. P. Hydroxyl-radical-induced degradative oxidation of beta-lactam ant biotics in water: absolute rate constant measurements. J. Phys. Chem. A. 2010, 19, 8391–8395.
He X.; Mezyk S.P.; Michael I.; Fatta-Kassinos D.; Dinysiou D.D. Degradation kinetics and mechanism of ?-lactam antibiotics by the activation of H2O2 and Na2S2O8 under UV-254 nm irradiation. J. Hazard Mater. 2014, 30, 375–383.
Tsuji A.; Nakashima E.; Kagami I.; Yamana T. Intestinal absorption mechanism of amphoteric beta-lactam antibiotics I: Comparative absorption and evidence for saturable transport of amino-beta-lactam antibiotics by in situ rat small intestine. J. Pharm. Sci. 1981, 70, 768–772.
Sugawa M.; Saitoh H.; Iseki K.; Miyazaki K.; Arita T. Contribution of Passive Transport Mechanisms to the Intestinal Absorption of ??Lactam Antibiotics. J. Pharm. Pharmacol. 1990, 42, 314-318.
Hui Y.; Wang Q.; Ying S.; Ming S.; Li H. A New PAMPA Model Proposed on the Basis of a Synthetic Phospholipid Membrane. PLoS One. 2015, 10, 10.1371/journal.pone.0116502.
Blouin R. A.; Stoeckel K. Cefetamet pivoxil clinic pharmacokinetics. Clin. Pharmacokinet. 1993, 25, 172–188.
Ducharme M. P.; Edwards D. J.; McNamara P. J.; Stoeckel K. Bioavailability of syrup and tablet formulations of cefetamet pivoxil. Antimicrob. Agents Chemother. 1993, 37, 2706–2709.
Cullmann W.; Then R. L. Cefetamet: Its In Vitro Activity and Interaction with ?-Lactamases and Penicillin-Binding Proteins. Drug Invest. 1991, 3, 299–307.
Grover S. S.; Sharma M.; Chattopadhya M. D.; Kapoor H.; Pasha S. T.; Singh G. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin. J. Infect. 2006, 53, 279–288.
Yang K.; Guglielmo B. J. Diagnosis and treatment of extended- spectrum and AmpC beta-lactamase-producing organisms. Ann. Pharmacother. 2007, 41, 1427–1435.
Luzzaro F.; Brigante G.; D’Andrea M. M.; Pini B.; Giani T.; Mantengoli E.; Rossolini G. M.; Toniolo A. Spread of multidrug- resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int. J. Antimicrob. Agents 2009, 33, 328-333.
Downloads
Published
How to Cite
Issue
Section
License
All articles published in Journal of Advances in Linguistics are licensed under a Creative Commons Attribution 4.0 International License.
